Broker notes, analysis and comments
SigmaRoc Plc (LON:SRC) is the topic of conversation when Zeus Capital Director of Mining and Metals talks to DirectorsTalk about its latest acquisition. Nick talks us through the acquisition of..
Chamberlin Plc (LON:CMH) remains on track strategically, developing its product offering to the automobile turbocharger industry through expansion of its principal operational facilities. Revenue growth is meeting expectations but one-off..
Alliance Pharma Plc (LON:APH) buy-and-build strategy is to evolve into a profitable, cash generative, specialty pharma business is bearing fruit. Acquisition of the dermatology and wound care products from Sinclair..
Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology..
Flowtech Fluidpower Plc (LON:FLO) has announced its fifth major acquisition and sixth in total this year. Group HES Ltd has been acquired to continue the build out the PMC division..
Despite enjoying a flood of investment in July, the level of new funds finding their way into AIM’s Oil & Gas Exploration & Production sector slowed to a trickle in..
Tissue Regenix Group Plc (LON:TRX) has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since..
Vertu Motors Plc (LON:VTU) has reported another record performance for H1 2018, with adjusted EPS +5% ahead of our expectations. We maintain our FY 2018 assumptions at this juncture but..
Allergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in the EU only..
The 1Q trading update from City of London Investment Group Plc (LON:CLIG), a leading specialist asset management group focused on emerging markets and closed-end funds, reveals: 1Q rise of 6%..
Motorpoint Group Plc (LON:MOTR) has released a trading update this morning confirming a solid H1 performance with over 18% revenue growth. While we recognise there is an element of consumer..
ValiRx Plc (LON:VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are..
MelodyVR, the leading creator of virtual reality content focused on the music industry and subsidiary of EVR Holdings Plc (LON:EVR), this morning announces that it has entered into a VR..
A recent visit to Avanco Resources Limited (ASX:AVB) projects in northern Brazil confirmed our belief that the group’s portfolio has significant growth potential, and that the company has a management..
Scancell Holdings Plc (LON:SCLP) is a clinical stage pharmaceutical company developing two distinct flexible cancer immunotherapy platforms, each with broad applications. ImmunoBody is a DNA vaccine which stimulates high avidity..
Advanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world renowned CERN. The company is entering an..
In 2016 Sinclair Pharma Plc (LON:SPH) was transformed into a streamlined, pure-play aesthetics company with a concentrated, competitive portfolio of differentiated injectable products. Effective, longer-lasting, natural looking, minimally invasive treatments..
ValiRx Plc (LON:VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are..
Purplebrick Group Plc (LON:PURP) AGM trading update confirms that it has made a “strong start” to the current financial year to 30 April 2018 and “trading in the UK and..
Gym Group Plc (LON:GYM) Valuing high growth companies can be tricky. The cost of establishing growth tends to drag down current earnings, making the company look expensive on straight PE..
